CA2043088A1 - Method of cloning mammalian embryos - Google Patents
Method of cloning mammalian embryosInfo
- Publication number
- CA2043088A1 CA2043088A1 CA 2043088 CA2043088A CA2043088A1 CA 2043088 A1 CA2043088 A1 CA 2043088A1 CA 2043088 CA2043088 CA 2043088 CA 2043088 A CA2043088 A CA 2043088A CA 2043088 A1 CA2043088 A1 CA 2043088A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleus
- donor
- oocyte
- embryo
- recipient oocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001161 mammalian embryo Anatomy 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 68
- 238000010367 cloning Methods 0.000 title abstract description 16
- 210000000287 oocyte Anatomy 0.000 claims abstract description 104
- 238000012423 maintenance Methods 0.000 claims abstract description 37
- 241000283690 Bos taurus Species 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 230000006872 improvement Effects 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 52
- 238000012546 transfer Methods 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 24
- 210000001109 blastomere Anatomy 0.000 claims description 16
- 230000007910 cell fusion Effects 0.000 claims description 11
- 230000031864 metaphase Effects 0.000 claims description 9
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 229930182816 L-glutamine Natural products 0.000 claims description 4
- 210000000110 microvilli Anatomy 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- 230000002759 chromosomal effect Effects 0.000 claims description 3
- 238000003501 co-culture Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 description 56
- 210000002257 embryonic structure Anatomy 0.000 description 41
- 239000002609 medium Substances 0.000 description 32
- 230000004927 fusion Effects 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- 210000002459 blastocyst Anatomy 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 238000010449 nuclear transplantation Methods 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000007159 enucleation Effects 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 6
- 210000003101 oviduct Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000000625 blastula Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000000472 morula Anatomy 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241001665167 Solter Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 244000309465 heifer Species 0.000 description 4
- 210000004508 polar body Anatomy 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004340 zona pellucida Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 3
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 238000004720 dielectrophoresis Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 241000269332 Ambystoma mexicanum Species 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 229940116871 l-lactate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000224421 Heterolobosea Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000270942 Rana pipiens Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000002380 oogonia Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Method of Cloning Mammalian Embryos ABSTRACT OF THE DISCLOSURE
An improved method of cloning mammalian embryos by transferring a nucleus from a donor mammalian embryo to an enucleated recipient oocyte and culturing the nuclear transferred bovine embryo in vitro is described.
The improvement includes positioning the donor embryo nucleus adjacent to the enucleated recipient oocyte, and maintaining the nucleus and oocyte in a maintenance medium for a time sufficient to increase the intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte prior to fusing the donor nucleus to the recipient oocyte.
An improved method of cloning mammalian embryos by transferring a nucleus from a donor mammalian embryo to an enucleated recipient oocyte and culturing the nuclear transferred bovine embryo in vitro is described.
The improvement includes positioning the donor embryo nucleus adjacent to the enucleated recipient oocyte, and maintaining the nucleus and oocyte in a maintenance medium for a time sufficient to increase the intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte prior to fusing the donor nucleus to the recipient oocyte.
Description
3 ~
FIELD OF THE INVENTION
The present invention is generally directed to an improved process for cloning or multiplying mammalian embryos and to an improved process for transferring the nuclei of donor embryos into enucleated recipient oocytes, that is, oocytes from which the nuclei have been removed. The present invention is specifically directed to enhancing mammalian embryo development after nuclear transfer by including a maintenance period prior to fusion which promoted increased intercellular surface area contact.
DESCRIPTION OF THE PRIOR ART
Advanced genetic improvement and selection techniques continue to be sought in the field of animal husbandry. With specific reference to dairy cattle, for example, significant increases in milk production have been made with the wide scale use of genetieally superior sires and artificial insemination. Dairy COW6 today produce nearly twice as much milk as they did 30 years ago. Further genetic improvement can be accomplished by the multiplication of superior or genetically manipulated embryos by cloning.
It has now becom~ an accepted practice to transplant embryos in cattle to aid in the production of genetically superior stock. The cloning of embryos together with the ability to transplant the cloned embryos makes it possible to produce multiple genetically identical animals. Embryo cloning is the proeess of transferring the nucleus of an embryonic donor cell to an enucleated recipient ovum or oocyte. The clone then -3~ 3ti~
develops into a genetically identical offspring to the donor embryo.
Nuclear transfer was first accomplished in Amoeba sphaeronucleus in 1939 by Comandon and de Fonbrune ("Greffe Nucleaire Totale, Simple ou Multiple, Chez une Amibe," Soc. Biol. 130: 744, 1939). This was followed in 1952 by successful nuclear transfer in Rana PiPiens by Briggs and King ("Transplantation of Living Nuclei from Blastula Cells into Enucleated Frogsl Eggs," Zooloqy 38:
455-463, 1952). The procedure for successful nuclear transfers, according to Briggs and King (supra), included the following:
l) activation of a recipient oocyte:
FIELD OF THE INVENTION
The present invention is generally directed to an improved process for cloning or multiplying mammalian embryos and to an improved process for transferring the nuclei of donor embryos into enucleated recipient oocytes, that is, oocytes from which the nuclei have been removed. The present invention is specifically directed to enhancing mammalian embryo development after nuclear transfer by including a maintenance period prior to fusion which promoted increased intercellular surface area contact.
DESCRIPTION OF THE PRIOR ART
Advanced genetic improvement and selection techniques continue to be sought in the field of animal husbandry. With specific reference to dairy cattle, for example, significant increases in milk production have been made with the wide scale use of genetieally superior sires and artificial insemination. Dairy COW6 today produce nearly twice as much milk as they did 30 years ago. Further genetic improvement can be accomplished by the multiplication of superior or genetically manipulated embryos by cloning.
It has now becom~ an accepted practice to transplant embryos in cattle to aid in the production of genetically superior stock. The cloning of embryos together with the ability to transplant the cloned embryos makes it possible to produce multiple genetically identical animals. Embryo cloning is the proeess of transferring the nucleus of an embryonic donor cell to an enucleated recipient ovum or oocyte. The clone then -3~ 3ti~
develops into a genetically identical offspring to the donor embryo.
Nuclear transfer was first accomplished in Amoeba sphaeronucleus in 1939 by Comandon and de Fonbrune ("Greffe Nucleaire Totale, Simple ou Multiple, Chez une Amibe," Soc. Biol. 130: 744, 1939). This was followed in 1952 by successful nuclear transfer in Rana PiPiens by Briggs and King ("Transplantation of Living Nuclei from Blastula Cells into Enucleated Frogsl Eggs," Zooloqy 38:
455-463, 1952). The procedure for successful nuclear transfers, according to Briggs and King (supra), included the following:
l) activation of a recipient oocyte:
2) enucleation, i.e., the process of removing or inactivating the chromosomes from the recipient oocyte;
and
and
3) transfer of a whole blastomere (a cell resulting from embryo cleavage prior to gastrulation) with a nucleus, from a blastula or early gastrula stage embryo back to the enucleated oocyte.
Embryo cloning has now been successfully performed in cattle, sheep, rabbits, pigs and mice (Prather, R.S. et al., 1987, Biol. ReProd., 37: 859-866;
~'illadsen, S.M., 1986, Nature, 320: 63-65; Stice, S.L., and J.M. Robl, 1989, Biol. Reprod., 39: 657-664; Prather, R.S. et al. r 1989, Biol. Reprod., 41: 414-418; Tsunoda, Y. et al., :L987~ J. Ex~. Zool., 242: 147-151).
Elsdale et al. ("A Description of the Technique for Nuclear Transplantation in XenoPus laevis," J.
Embrvol. EXP. MorPh., 8(4): 437-444, 1960), utilized ultraviolet irradiation to, in one step, inactivate thP
egg pronucleus and activate the unfertilized oocyte. In the axolotl, activation was reported by electrical shock with chromosomes of the egg nucleus being eliminated by ultraviolet irradiation, (Briggs, R., et al. r "Transplantation of Nuclei of Various Cell Types from Neurulae of the Mexican Axolotl (Ambvstoma meXlCanUm),"
J . ~ C .~
Develop. Biol. 10: 233, 1964). Transfer of a whole blastomere containing a nucleus into the enucleated oocyte via a small bore micropipette was the common method of nuclear transfer for all these techniques.
Two techniques have been used for nuclear transfer in the mouse. Illmensee and Hoppe used a totally surgical method in which a micropipette was inserted through the plasma membrane and into the cytoplasm of a pronuclear stage embryo for pronuclear removal and subsequent insertion of donor nuclei (Illmensee, K~ and Hoppe, P.C., "Nuclear Transplantation in Mus musculus: Development Potential of Nuclei from Preimplantation Embryos," Cell 23: 9, 1981). McGrath and Solter reported a nondisruptive method of transplanting nuclei (McGrath, J. and Solter D., "Nuclear Transplantation in the Mouse Embryo by Microsurgery and Cell Fusion," Science, 220: 1300, 1983)~ Nuclei were removed as membrane bounded pronuclear karyoplasts without penetrating the plasma membrane of the embryo.
The nucleus was inserted into a recipient cell by cell fusion, using Sendai virus as the fusigenic agent. A
small volume of Sendai virus suspension was aspirated after removal of the donor nucleus and the virus suspension and the pronuclear karyoplasts were injected sequentiall~y into the perivitelline space of the recipient embryo. At best, the microsurgical method of Illmensee and Hoppe (supra) was about 30-40% e~icient, whereas the nondisruptive method of McGrath and Solter (su~ra) was greater than 90% efficient. These techniques have been successful in producing blastocyst stage embryos which do not continue development to term.
Reports that Illmensee and Hoppe produced three live mice have been questioned.
It was later reported that blastocyst stage embryos and mice were produced by transferring nuclei into enucleated pronuclear zygotes only when the donor cell stage was also pronuclear or at a very early two-2~3~8 cell stage (McGrath, J. and Solter, D., "Inability of Mouse ~lastomere Nuclei Transferred to Enucleated Zygotes to Support Development In Vitro," Science, 226: 1317-1319, 1984; Surani, M.A.H. et al., "Nuclear Transplantation in the Mouse: Heritable Differences Between Paternal Genomes after Activation of the Embryonic Genome." Cell, 45: 127-136; 1986; and Robl, J.M. et al., "Nuclear Transplantation in Mouse Embryos:
Assessment of Recipient Cell Stage," Biol. Reprod., 34:
733-739, 1986).
While cloning procedures have been successful for a variety of species, the embryo development after nuclear transfer is lower than non-manipulated contemporaries (Bondioli, K.R. et al. 1990, "Production of Identical Bovine Offspring by Nuclear Transfer,"
Therioaenoloay, Vol. 13, No. 1, pgs. 165-174).
Embryo development after nuclear transfer has been improved by various procedures invoIving arresting the embryo cytoskeleton with a cytochalasin B culture during cell fusion. Cytochalasin causes the embryo cytoskeleton to become more elastic, making the embryo more conducive to cell fusion (McGrath, J. and Solter, D., 1983, supra.). It is believed that periods of cytoskeletal repair before cell fusion may increase subsequent embryo development.
SUMMARY OF THE INVENTION
The present invention is directed to a technique which improves known methods of producing cloned mammalian embryos by transferring a nucleus from a donor embryo to a recipient oocyte. The improved cloning method includes isolating a donor membrane-bounded nucleus from a cell of a donor embryo, removinq the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte, maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte for a period of time sufficient to increase ~ - .
-6- ~ 8 intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte, and fusing the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte together to form an embryonic single cell with a nucleus from the donor embryo, referred to herein as a "nuclear transfer embryo" or an "NT". The improvement of this invention lies in the maintenance period prior to fusion.
By maintaining the nuclells of the membrane-bounded donor embryo and the enucleated recipient oocyte in a maintenance medium for an elongated period of time, typically 24 - 52 hours after oocyte aspiration from ovarian follicles, the nucleus and oocyte undergo a physiological change which enhances the ability of each of the membranes to fuse. This results in increased fusion and developmental rates.
Further objects, features and advantages of the present invention will be apparent from the following detailed description and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to an improvement in the series of steps which collectively result in the cloning of mammalian embryos by nuclear transplantation. Although it is contemplated that the embryo cloning procedure of the present invention may be utilized on a variety of mammals, the procedure will be described with reference to the bovine species. However, the present invention does not restrict the cloning procedure to bovine embryos.
The cloning procedure includes a non-disruptive method of removing the nucleus from a mature recipient oocyte and isolating a nucleus from a donor embryo, bounded by a membrane, either by removal of the nucleus 3~ from the donor embryo or by isolating a blastomere itself. The nucleus is then positioned so it is adjacent -7-- ~ é~ 8 to the recipient oocyte and the nucleus is fused with the recipient cell to form an embryonic single cell.
The standard embryo cloning process follows a basic six step procedure:
1) selecting a proper recipient oocyte and a multicellular embryo donor for nuclear transfer 2) isolating a blastomere from the donor;
3) enucleating, i.e., removing the nuclear material from the recipient oocyte;
Embryo cloning has now been successfully performed in cattle, sheep, rabbits, pigs and mice (Prather, R.S. et al., 1987, Biol. ReProd., 37: 859-866;
~'illadsen, S.M., 1986, Nature, 320: 63-65; Stice, S.L., and J.M. Robl, 1989, Biol. Reprod., 39: 657-664; Prather, R.S. et al. r 1989, Biol. Reprod., 41: 414-418; Tsunoda, Y. et al., :L987~ J. Ex~. Zool., 242: 147-151).
Elsdale et al. ("A Description of the Technique for Nuclear Transplantation in XenoPus laevis," J.
Embrvol. EXP. MorPh., 8(4): 437-444, 1960), utilized ultraviolet irradiation to, in one step, inactivate thP
egg pronucleus and activate the unfertilized oocyte. In the axolotl, activation was reported by electrical shock with chromosomes of the egg nucleus being eliminated by ultraviolet irradiation, (Briggs, R., et al. r "Transplantation of Nuclei of Various Cell Types from Neurulae of the Mexican Axolotl (Ambvstoma meXlCanUm),"
J . ~ C .~
Develop. Biol. 10: 233, 1964). Transfer of a whole blastomere containing a nucleus into the enucleated oocyte via a small bore micropipette was the common method of nuclear transfer for all these techniques.
Two techniques have been used for nuclear transfer in the mouse. Illmensee and Hoppe used a totally surgical method in which a micropipette was inserted through the plasma membrane and into the cytoplasm of a pronuclear stage embryo for pronuclear removal and subsequent insertion of donor nuclei (Illmensee, K~ and Hoppe, P.C., "Nuclear Transplantation in Mus musculus: Development Potential of Nuclei from Preimplantation Embryos," Cell 23: 9, 1981). McGrath and Solter reported a nondisruptive method of transplanting nuclei (McGrath, J. and Solter D., "Nuclear Transplantation in the Mouse Embryo by Microsurgery and Cell Fusion," Science, 220: 1300, 1983)~ Nuclei were removed as membrane bounded pronuclear karyoplasts without penetrating the plasma membrane of the embryo.
The nucleus was inserted into a recipient cell by cell fusion, using Sendai virus as the fusigenic agent. A
small volume of Sendai virus suspension was aspirated after removal of the donor nucleus and the virus suspension and the pronuclear karyoplasts were injected sequentiall~y into the perivitelline space of the recipient embryo. At best, the microsurgical method of Illmensee and Hoppe (supra) was about 30-40% e~icient, whereas the nondisruptive method of McGrath and Solter (su~ra) was greater than 90% efficient. These techniques have been successful in producing blastocyst stage embryos which do not continue development to term.
Reports that Illmensee and Hoppe produced three live mice have been questioned.
It was later reported that blastocyst stage embryos and mice were produced by transferring nuclei into enucleated pronuclear zygotes only when the donor cell stage was also pronuclear or at a very early two-2~3~8 cell stage (McGrath, J. and Solter, D., "Inability of Mouse ~lastomere Nuclei Transferred to Enucleated Zygotes to Support Development In Vitro," Science, 226: 1317-1319, 1984; Surani, M.A.H. et al., "Nuclear Transplantation in the Mouse: Heritable Differences Between Paternal Genomes after Activation of the Embryonic Genome." Cell, 45: 127-136; 1986; and Robl, J.M. et al., "Nuclear Transplantation in Mouse Embryos:
Assessment of Recipient Cell Stage," Biol. Reprod., 34:
733-739, 1986).
While cloning procedures have been successful for a variety of species, the embryo development after nuclear transfer is lower than non-manipulated contemporaries (Bondioli, K.R. et al. 1990, "Production of Identical Bovine Offspring by Nuclear Transfer,"
Therioaenoloay, Vol. 13, No. 1, pgs. 165-174).
Embryo development after nuclear transfer has been improved by various procedures invoIving arresting the embryo cytoskeleton with a cytochalasin B culture during cell fusion. Cytochalasin causes the embryo cytoskeleton to become more elastic, making the embryo more conducive to cell fusion (McGrath, J. and Solter, D., 1983, supra.). It is believed that periods of cytoskeletal repair before cell fusion may increase subsequent embryo development.
SUMMARY OF THE INVENTION
The present invention is directed to a technique which improves known methods of producing cloned mammalian embryos by transferring a nucleus from a donor embryo to a recipient oocyte. The improved cloning method includes isolating a donor membrane-bounded nucleus from a cell of a donor embryo, removinq the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte, maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte for a period of time sufficient to increase ~ - .
-6- ~ 8 intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte, and fusing the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte together to form an embryonic single cell with a nucleus from the donor embryo, referred to herein as a "nuclear transfer embryo" or an "NT". The improvement of this invention lies in the maintenance period prior to fusion.
By maintaining the nuclells of the membrane-bounded donor embryo and the enucleated recipient oocyte in a maintenance medium for an elongated period of time, typically 24 - 52 hours after oocyte aspiration from ovarian follicles, the nucleus and oocyte undergo a physiological change which enhances the ability of each of the membranes to fuse. This results in increased fusion and developmental rates.
Further objects, features and advantages of the present invention will be apparent from the following detailed description and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to an improvement in the series of steps which collectively result in the cloning of mammalian embryos by nuclear transplantation. Although it is contemplated that the embryo cloning procedure of the present invention may be utilized on a variety of mammals, the procedure will be described with reference to the bovine species. However, the present invention does not restrict the cloning procedure to bovine embryos.
The cloning procedure includes a non-disruptive method of removing the nucleus from a mature recipient oocyte and isolating a nucleus from a donor embryo, bounded by a membrane, either by removal of the nucleus 3~ from the donor embryo or by isolating a blastomere itself. The nucleus is then positioned so it is adjacent -7-- ~ é~ 8 to the recipient oocyte and the nucleus is fused with the recipient cell to form an embryonic single cell.
The standard embryo cloning process follows a basic six step procedure:
1) selecting a proper recipient oocyte and a multicellular embryo donor for nuclear transfer 2) isolating a blastomere from the donor;
3) enucleating, i.e., removing the nuclear material from the recipient oocyte;
4) introducing the membrane-bounded nucleus of the blastomere adjacent to the enucleated recipient oocyte;
5) orienting the nucleus and the recipient oocyte for cell fusion; and
6) fusing the membrane surrounding the nucleus to the membrane of the recipient oocyte and activatiny the recipient oocyte by dielectrophoresis.
The overall procedure disrlosed herein may be described as cloning or as multiplication of embryos by nuclear transfer followed by a prolonged maintenance period to increase fusion and developmental rates of multiple genetically identical embryos, and ultimately, animals.
Donor Cell EmbrYos The donor embryos may be obtained by flushing from surgically recovered oviducts or may be nonsurgically flushed from the uterus in manners known to the art. The donor embryo is selected prior to any significant cellular differentiation. In other words, totipotent embryonic stem cells are used, which are defined as those cells still capable of differentiation to eventually form all the required embryonic cell typesO
While not wishing to be limited to a particular cell division stage, a preferred donor embryo would have a development of from 2-64 cells. It is, however, within the scope of the present invention to include donor embryos at later stages of development as long as ~3~g8 significant cell differentiation has not occurred in the donor embryo being used. For example, the inner cell mass of a later stage embryo may remain totipotent (that is, may not have undergone significant cellular differentiation) whereas the outer cells of the same embryo may have begun differentiation to an extent where they are not totipotent and not suitable for use here.
Methods of in vitro maturation, fertilization and development also can be used to generate donor embryos. Donor embryos at the 16-64 cell stage are sometimes referred to as morula rather than blastula.
Nevertheless, for convenience the term blastula will be used herein to refer to the embryo, regardless of age, and the term blastomere will be used to refer to a single cell from any such embryo.
The nucleus of the donor embryo should be membrane-bounded to be used optimally in the procedure.
Such a membrane-bounded nucleus may either consist of an entire blastomere or may consist of a karyoplast, which is an aspirated cellular subset including a nucleus and a small amount of cytoplasm bounded by a plasma membrane.
Micromanipulation of the embryos is performed in a manner similar to the methods of McGrath and Solter tsupra.), which is incorporated herein for details of the micromanipulation technique. Micromanipulation is performed using a cell holding pipette, having an outer diameter of about 120 to 180 micrometers and an inner diameter of approximately 25 to 35 micrometers, and a beveled, sharpened enucleation and transfer pipette having an outer diameter of approximately 10 to 45 micrometers, depending upon the size of the blastomere.
The donor embryos may optionally be treated with cytochalasin B. The nuclei of the donor embryos are prepared for transfer either by aspirating a part of the blastomere which contains the nucleus, thus creating a karyoplast, or by aspirating the entire blastomere.
Aspirating the entire blastomere is preferred.
9 ~ 3 ~
Culture and Maintenance Media There are a vaxiety of embryo culture and maintenance media routinely used for the collection of embryos, and specifically bovine embryos. Examples of known media, which may be used for bovine embryo culture and maintenance, include Ham's F-10 + 10% fetal calf serum, Iissue Culture Medium-199 (TC~ 199) + 10% fetal calf serum, Tyrodes's-Albumin-Lactate-Pyruvate, Dulbecco's Phosphate Buffered Saline, Eagle's and Whitten's media. One of the most common media for the collection and freezing of embryos is Dulbecco's Phosphate Buffered Saline (PBS) incorporating 1 to 20%
fetal calf serum, new born serum or steer serum. If the embryos are to be kept in an embryo culture medium for a substantial period of time, the PBS is normally supplemented with 10 to 20% serum.
Eyestone, et al., "Culture of One- and Two-Cell Bovine Embryos to the Blastocyst Stage in the Ovine Oviduct", Therioqenoloqv, Vol. 28, pp. 1-7 (1987), reported that ligated ovine oviducts would support development of bovine embryos from the l-cell to blastocyst stage. Pregnancies and live calves were produced after transfer of cultured embryos to recipient heifers. Cultures of 1- and 2-cell embryos in the oviducts of intact cycling, ovariectomized or anestrous ewes produced morphologically normal morulae and blastocysts followed by pregnancies in recipient heifers, suggesting that ovarian activity was not required for normal embryo development in the oviduct.
Another embryo culture and maintenance medium is described in parent patent application serial number 07/558,969 to Rosenkrans, Jr. et al., entitled "Bovine Embryo Medium," which is incorporated herein by reference. This embryo medium, named CR1, comprises a culture solution containing the nutritional substances necessary to support an embryo and is the preferred maintenance medium for use with this invention. The - l o - ~ 8 medium contains hemicalcium L-~actate in amounts ranging from 1.0 m~, to 10 mM, preferably 1.0 mM to 5.0 mM.
~emicalcium L-lactate is L-lactate with a hemicalcium salt incorporated thereon. Hemicalcium L-lactate is significant in that a single component satisfies two major requirements in the culture medium: 1) the calcium requirement necessary for compaction and cytoskeleton arrangement; and 2) the lactate requirement necessary for metabolism and electron transport. Hemicalcium L-lactate also serves as valuable mineral and energy source for the medium necessary for viability of the embryos.
Advantayeously, CRl medium does not contain serum, such as fetal calf serum, and does not require the use of a co-culture of animal cells or other biological media, i.e, media comprising animal cells, e.g., oviductal cells. Biological media can sometimes be disadvantageous in that they may contain trace factors which may be harmful to the embryos and which are difficult to detect, characterize and eliminate.
Examples of the main components in CR1 medium include hemicalcium L-lactate, sodium chloride, potassium chloride, sodium bicarbonate and a minor amount of fatty-acid free bovine serum albumin. Additionally, a defined quantity of essential and non-essential amino acids may be added to the medium.
Salts are added to the medium to maintain a proper osmotic pressure or osmolarity of the medium. The preferred osmotic pressure is 265 milli-osmoles (mOSM).
The concentration of salt generally ranges from 0 Mm to 155 Mm, preferably 110 mM to 115 mM. Examples of salts include sodium chloride and potassium chloride, preferably sodium chloride.
The fatty-acid free BSA is added as a surfactant, i.e., to prevent the embryos from adhering 'o each other. Unlike culture media known to the art, the CRl medium requires only a minimal amount of the fatty-acid free BSA. The fatty-acid free BSA is added in ( S
amounts ranging from 1 mg/ml to 6 mg/ml, preferably 1 mg/ml to 3 mg/ml, and most preferably 3.0 mg/ml.
Antibiotically effective amounts of an agent, such as gentamicin sulfate, penicillin, streptomycin, fungizone or other antibiotics known to the art. Additionally, a cryopreservation agent, known to the art, may be added to protect the cellular integrity of the bovine embryo during freezing operations. Further, chemical buffers, such as HEPES, may by added to maintain the proper pH in 10 the absence of CO2.
CRl medium preferably contains the following components in the following quantities:
sodium chloride - 114.7 mM
potassium chloride - 3.1 mM
sodium bicarbonate - 26.2 mM
hemicalcium L-lactate - 5 m~
fatty-acid free BSA - 3 mg/ml Oocyte The "oocyte," as used here for the recipient oocyte, means an oocyte which develops from an oogonium and, following meiosis, becomes a mature ovum. It has been found that not all oocytes are equally optimal cells for efficient nuclear transplantation in mammals. For 25 purposes of the present invention, metaphase II stage oocytes, matured either in vivo or in vitro, have been found to be optimal. Mature metaphase II oocytes may be collected surgically from either nonsuperovulated or superovulated cows or heifers 35 to 48 hours past the 30 onset of estrus or past an injection of human Chorionic Gonadotrophin (hCG) or similar hormone. Alternaiively, immature oocytes may be recovered by aspiration from ovarian follicles obtained from slaughtered cows or heifers and then may be matured in vitro in a maturation 35 medium by appropriate hormonal treatment and culturing.
As stated above, the oocyte is allowed to mature in a known maturation medium until the oocyte enters the -12~ u i~
metaphase II stage, generally 18-24 hours post aspiration. For purposes o~ the present invention, this period Or time is known as the "maturation period." As used herein for calc~1lation of time periods, "aspiration"
refers to aspiration of the immature oocytes from ovarian follicles.
Mature oocytes can be first treated with cytochalasin B at about 7.5 micrograms per milliliter, or an effectively similar microtubal inhibitor at a concentration sufficient to allow the enucleation and transfer pipette to be inserted through the zona pellucida to allow for removal of a portion of the cytoplasm without, at any point, actually rupturing the plasma membrane. The mature oocyte is first held in place by mild suction by the cell holding pipette. The enucleation and transfer pipette is then inserted through the zona pellucida of the oocyte at the point of either the metaphase II bulge or adjacent to the first polar body, i.e., in a location intended to be adjacent to the metaphase chromosomes. The pipette does not penetrate the plasma membrane. Aspiration applied through the pipette draws a portion of the cytoplasm into the pipette which includes, in the case of the metaphase II bulge, the entire bulge surrounding cytoplasm, or, in the case of the firs1- polar body, the cytoplasm adjacent to the polar body. This process is intended to draw all the metaphase chromosomes into the pipette. As the pipette is withdrawn, with suction maintained, the plasma membrane is stretched and then seals itself leaving a competent plasma membrane on the enucleated oocyte.
Maintenance Period Prior to fusing the membranes of the donor membrane-bounded nucleus and the enucleated ~ecipient oocyte together, it has been found that maintaining the nucleus and the oocyte together in the embryo maintenance medium significantly improves the development of the embryo post fusion. The nucleus and the oocyte are allowed to remain in the maintenance medium for a period of about 6-2~ hours, preferably about 10-18 hours, after the oocyte maturation period to align the oocyte adjacent the membrane of the nucleus. Calculated from oocyte aspiration, the maintenance period will be about 24-52 hours, preferably 78-42 hours, post aspiration.
Without wishing to be held to one particular explanation for the advantages of maintaining the donor embryo nucleus and the recipient oocyte in a maturation medium for an extended time prior to fusion, it is believed that the maintenance period increases the intercellular surface area contact by the creation of tiny microvilli on the surface of the donor membrane-bounded nucleus and the enucleated recipient oocyte.
With the increased amounts of microvilli, there are increased intercellular connections, i.e., projections which will attract and adhere the donor embryo nucleus to the recipient oocyte.
The transfer pipette, carr~ing the aspirated membrane-bounded nucleus, is then inserted through ~he zona pellucida of the recipient enucleated oocyte; and the membrane-bounded nucleus is deposited under the zona pellucida with lts membrane abutting the plasma membrane of the recipient oocyte.
Fusion of the Nucleus and the Oocvte At approximately 24-52 hours, preferably 28-42 hours post aspiration or, stated differently, 6-28 hours, preferably 10-18 hours, after the nucleus is positioned such that its membrane is adjacent the enucleated oocyte, the cell surface contact appears to be at its peak. It is on this basis that membrane fusion may be enhanced with the use of the maintenance period of this invention.
The onset of electricity, via the electrofusion technique, serves to induce the fusion process. Although electrofusion is preferred, it is within the scope of the ~ 3 ~ ~3 i3 ~ 8 present invention to utilize other fusion techniques.
For example, fusion can be accomplished using Sendai virus as a fusigenic agent.
In the preferred embodiment, fusion of the membrane-bounded nucleus with the enucleated recipient oocyte and simultaneous activation of the recipient oocyte are carried out by a single dielectrophoresis step using commercially available electrofusion equipment which is described below. Prior to electrofusing the donor embryo nucleus and enucleated recipient oocyte together, it is necessary to orient the cell membranes in the electric field. The term "orientation" as used herein is defined as the placement of the two cells such that the plane of contact of the two membranes, i.e., the plasma membrane of the body carrying the donor nucleus and the plasma membrane of the recipient oocyte, which will become fused together, is perpendicular to the electrical field. It has been found that random orientation results in a marked reduction in the s~ccessful fusion rate. If cells are oriented such that the fusion membranes are parallel, or at approximately a 45~ angle, to the electrical field, the rate of successful fusion will decrease. The alignment may be done electrically or mechanically. If the size of the two cells is not greatly disproportionate, a small alignment alternating-current voltage (-5 volts per millimeter at 1000 KHz) for a short time (10 seconds) will cause the cells to reorient with their membranes apposed. Repeated pulses may be needed. If the cells vary greatly in size, mechanical manipulation ~ay be required to properly orient the membranes.
The actual incorporation of a donor nucleus into an enucleated oocyte is conducted by a dielectrophoretic method of cell fusion, using a DC
current and using a non-conductive, i.e., non-ionic, media such as a mannitol solution, sorbitol or sucrose (Zimmerman) based cell fusion media. The fusion ~30~
phenomenon is the result of cell membrane breakdown and pore formation between properly oriented opposing cells.
The pores, or small channels, created between the two cells are thermodynamically unstable because of the high surface curvature of the channels and the associated high tension in the membrane. This instability causes the channels to merge and enlarge until the membranes form a single cell which contains the nucleus from the donor embryo cell.
Post-Fusion Culture ~he embryonic single-cell clones produced as described herein preferably are cultured, either in vitro or in vivo, to the morula or blastula stage. For example, the clones may be cultured in the oviduct of sheep, or other suitable animal, or in a suitable culture medium. The embryos then may be transplanted into the uteri of cattle at a suitable stage of the estrous cycle.
The procedures for transplantation are commonly known and practiced in the embryo transfer field. A percentage of these transplants will initiate pregnancies in the maternal surrogates. Animals born of these pregnancies will be genetically identical where the donor cells were from a single embryo or a clone thereof.
The following example is offered by way of illustration and not by way of limitation~
EXPERIMENTAL PROCEDURES
Source of Recipient Oocvtes and Donor Em~rvos. The oocyte-cumulus complexes (OCC) were aspirated from bovine ovaries recovered from a slaughterhouse in Milwaukee, WI.
The ovaries were transported from the slaughterhouse to the laboratory in insulated containers with saline (.9%;
30 + 2C). After arrival, the ovaries were washed with 30C water and placed into a flask containing fresh saline (.9%) in a water bath maintained at 30C.
Follicular contents were harvested by aspiration using an 18-gauge needle and accumulated in a 50 ml sterile conical tube (Falcon #2070). Following aspiration, OCC
were located using 100 mm plates in a warm room ~30 2C) using a stereomicroscope. The OCC were washed 4 times through low bicarbonate-TALP (Parrish, J. J. et al., (1988, "Capacitation of Bovine Sperm by Heparin,"
Biol. Re~rod. 38, 1171-1180, incorporated herein by reference~ and placed into maturation plates (10 OCC per 50 ul drop). Maturation plates consist of ten 50 ul drops of maturation medium with estradiol-17~ (1 ug/ml), FSH (.5 ug/ml~ and LH (.5 ug/ml) (Sirard et al., Biol.
Reprod., 39, pgs. 546-552, 1988) in a 60 mm petri dish with 10 ml of paraffin oil.
Those oocytes not used as recipient oocytes were fertilized to provide donor embryos in subsequent experiments. Fertilization of oocytes was performed according to the procedure described in Sirard et al.
(su~ra., 1988). Briefly, OCC were in vitro matured 22 +
2 hours, then washed 2 times through Sp-TALP (Parrish, J.
J. et al, supra. 1988) and moved into fertilization plates. Fertilization was performed in 60 mm plates with 10 drops (40 ~l each) of fertilization medium (5 ml TL
Stock-no glucose, 30 mg fatty-free BSA-6 mglml final, 50 ~1 pyruvate stock-0.2 mM final, 2.5 ~l gentamicin-25 ~g/ml final-optional) covered with oil and 10 OCC for each drop. The OCC were added, followed by 5 X 104 motile sperm, .2 ug of heparin, and 2 ul of PHE stock (20 ~m penicillamine, 10 ~m hypotaurine, 1 ~m epinephrine, 21 ~m sodium metabisulfate, and 118 ~m DL-lactate syrup in .9% sodium chloride according to Leibfried, M. L. and B.
D. Bavister, 1982, "Effect of Epinephrine and Hypotaurine on in vitro Fertilization in the Golden Hamster," J.
Reprod. Fertil., 66, 87-93).
Motile sperm cells were prepared by the Percoll separation of frozen sperm procedure. A 45~ percoll solution (3.090 ml/100 ml KCl, 2.920 ml/100 ml NaH2PO4, ` -17- 2~3~8 4.675 g/100 ml NaCl, 2.380 g/100 ml HEPES, adjust the pH
to 7.3) was prepared by a 1:1 dilution with 90% percoll using Sperm TL Stock Solution (SPTL) (2.10 mM CaCl22H2O, 3.1 mM KCl, 0.4 mM MgC126H20, 100 mM NaCl, 0.29 mM
NaH2P04H20, 21.6 mM Lactic Acid, 10 mM Hepes, 25 mM
NaHCO3, adjust pH to 7.4 before bringing to final volume;
check osmolarity: 290-300 mOSM) according to Parrish, J.J. et al., supra. 1988. The SPTL did not contain BSA.
Two - three ml of 90% percoll was placed on the bottom of a conical tube (Falcon 2095). Two ml of 45% percoll was layered carefully on the top of the 90% percoll. The procedure was performed at room temperature. One unit of semen was thawed (35OC, l min.) and layered on top of the percoll gradients. The tube was centrifuged at 700 x g for 30 min. The top layers were removed, and the concentrated motile sperm was available for use.
Following 44 + 2 hours after insemination, the oCc were stripped of cumulus cells, and the eggs were categorized as cleaved (> 2 cells) or uncleaved. The cleaved eggs were cultured in CRl-L-Glutamine medium for 3 to 5 days until they reach the morula or blastocyst stage.
', ~ Embryo ~a~d nipulation.
Recipient oocytes were enucleated by aspirating approximately one-eighth to one-fourth the cytoplasm juxtaposed to the polar body or the metaphase bulge using a 10-45 micron transfer pipette, leaving an enucleated membrane-bounded oocyte. Embryos were manipulated in calcium and magnesium-free TL Hepes buffered modified Tyrodes medium prepared according to Bavister et 21., "Development of Preimplantation Embryos of the Golden Hamster in a Defined Culture Medium," Biol. Reprod., 28:
235, 1983). Nuclei from later stage donor embryos were removed by aspirating the nucleus and some surrounding membrane-bounded cytoplasm from a blastomere or by aspirating an entire blastomere. Micromanipulation was ~ ~r conducted using a holding pipette having an outer diameter of approximately 120-180 microns anà an inner diameter of approximately 30 microns and a beveled, sharpened enucleation and transfer pipette having an outer diameter of approximately 10 to 45 microns. Whole blastomeres, containing nuclei, were removed from donor embryos and positioned in the perivitelline space of the recipient oocytes by the method of McGrath and Solter (supra.).
Maintenance Procedures Embryos were maintained in vitro in CR1-L-Glutamine medium for 6-18 hours prior to fusion.
Zimmerman Cell Fusion Medium (GCA Corporation, Chicago, IL), was used for fusing donor and recipient cells.
Cells from donor embryos were washed in the medium then placed in the fusion chamber with the Zimmerman medium.
Following the fusion treatment, oocytes were placed in CR1-L-Glutamine medium, in 50 microliter drops, under paraffin oil in a humidified 5% C02 in air incubator and monitored for fusion and allowed to develop for five days.
Activation and fusion of the intact, membrane-bounded nuclei to the enucleated oocytes were carried out in Zimmerman Cell Fusion Medium by dielectrophoresis using a Zimmerman ~lectrofusion Instrument, GCA
Corporation, Chicago, IL. The fusion chamber consisted of two parallel electrodes 1 mm apart on a glass slide.
The instrument was adjusted in the following manner:
Fusion voltage: 80-120 volts (DC) Electrode distance: 1 mm Alignment voltage: 1-5 volts (AC) Alignment frequency: 1000 KHz Pulse duration: 10-~0 microseconds Postfusion alignment time: 5 seconds Number of Pulses: 1-6 Experiment ~ ~' $
The experiment was designed to determine whether the development of nuclear transfer embryos (NTs) could be improved by maintaining the donor embryo cells and recipients in maintenance medium for an extended period o~ time. NTs were produced according to Prather et al., 1987, Biol. Reprod., 37,859-866, which is incorporated herein by reference. Specifically, in vitro matured oocytes were used as recipients, in vitro developed embryos were used as donors, and the subsequently formed NTs were developed in vitro in CR1 with 1 mM L-glutamine medium (CR1-L-GLN).
The treatment structure was a blocked one-way design with 3 treatments. Each donor embryo served as the block, i.e., every treatment was imposed on donor embryo cells from each donor embryo. Enucleation and transfer of donor blastomeres was performed at 24 hours post-oocyte aspiration. The three treatments were as follows: 1) fusio~ at 30 hours; Z) those that did not fuse at 30 hours and were then refused at 42 hours; and 3) fusion at 42 hours. During the manipulation process, the donor and recipient embryo cells were handled in calcium and magnesium free TALP-hepes. The cells were maintained in CR1-L-GLN during the waiting period before fusion as well as is th~ post-fusion development period.
Embryos were developed in 50 microliter drops of this maintenance medium under paraffin oil in a humidified incubator with an atmosphere of 5% C02 in air. This experiment was replicated on three different days using three morula stage donor embryos (30-4~ cells each) on each day of nuclear transfer. The results are illustrated in the following table:
-20- ~ t ~
Nuclear Transfer - Fusion at 30 Hours Versus 42 hours -~ 1 IFUS~IOIY ACTIV~.TION ¦CLEAVAGE DEVELOPMENT
MORULA +
30 hr _ BLASTOCYST
% 56.9 71 32.0 4 7+3.7b N 31/42 l9J31 7J31 ~ 80.1 6309 22.2+6.7C
% 80.4 81 71.0 32.6+5.3C
a cultured 5 days in CR1 + L-Glutamine (1 mM) b,c uncommon superscripts differ (P<0.05) The results indicate that when the fusion regime is changed to a later time period, i.e., following the maintenance period of this invention, development of NTs is simi]ar to that of normal in vitro matured, fertilized and developed oocytes. Thus, the nuclear transfer embryo appears to have increased fusion and developmental rates when fusion is delayed by approximately 4-18 hours after the time fusion would normally take place, i.e., 34-48 hours after aspiration of the recipient oocytes.
It is understood that the invention is not confined to the pzrticular construction and arrangement herein described, but embraces such modlfied forms thereof as come within the scope of the following claims.
The overall procedure disrlosed herein may be described as cloning or as multiplication of embryos by nuclear transfer followed by a prolonged maintenance period to increase fusion and developmental rates of multiple genetically identical embryos, and ultimately, animals.
Donor Cell EmbrYos The donor embryos may be obtained by flushing from surgically recovered oviducts or may be nonsurgically flushed from the uterus in manners known to the art. The donor embryo is selected prior to any significant cellular differentiation. In other words, totipotent embryonic stem cells are used, which are defined as those cells still capable of differentiation to eventually form all the required embryonic cell typesO
While not wishing to be limited to a particular cell division stage, a preferred donor embryo would have a development of from 2-64 cells. It is, however, within the scope of the present invention to include donor embryos at later stages of development as long as ~3~g8 significant cell differentiation has not occurred in the donor embryo being used. For example, the inner cell mass of a later stage embryo may remain totipotent (that is, may not have undergone significant cellular differentiation) whereas the outer cells of the same embryo may have begun differentiation to an extent where they are not totipotent and not suitable for use here.
Methods of in vitro maturation, fertilization and development also can be used to generate donor embryos. Donor embryos at the 16-64 cell stage are sometimes referred to as morula rather than blastula.
Nevertheless, for convenience the term blastula will be used herein to refer to the embryo, regardless of age, and the term blastomere will be used to refer to a single cell from any such embryo.
The nucleus of the donor embryo should be membrane-bounded to be used optimally in the procedure.
Such a membrane-bounded nucleus may either consist of an entire blastomere or may consist of a karyoplast, which is an aspirated cellular subset including a nucleus and a small amount of cytoplasm bounded by a plasma membrane.
Micromanipulation of the embryos is performed in a manner similar to the methods of McGrath and Solter tsupra.), which is incorporated herein for details of the micromanipulation technique. Micromanipulation is performed using a cell holding pipette, having an outer diameter of about 120 to 180 micrometers and an inner diameter of approximately 25 to 35 micrometers, and a beveled, sharpened enucleation and transfer pipette having an outer diameter of approximately 10 to 45 micrometers, depending upon the size of the blastomere.
The donor embryos may optionally be treated with cytochalasin B. The nuclei of the donor embryos are prepared for transfer either by aspirating a part of the blastomere which contains the nucleus, thus creating a karyoplast, or by aspirating the entire blastomere.
Aspirating the entire blastomere is preferred.
9 ~ 3 ~
Culture and Maintenance Media There are a vaxiety of embryo culture and maintenance media routinely used for the collection of embryos, and specifically bovine embryos. Examples of known media, which may be used for bovine embryo culture and maintenance, include Ham's F-10 + 10% fetal calf serum, Iissue Culture Medium-199 (TC~ 199) + 10% fetal calf serum, Tyrodes's-Albumin-Lactate-Pyruvate, Dulbecco's Phosphate Buffered Saline, Eagle's and Whitten's media. One of the most common media for the collection and freezing of embryos is Dulbecco's Phosphate Buffered Saline (PBS) incorporating 1 to 20%
fetal calf serum, new born serum or steer serum. If the embryos are to be kept in an embryo culture medium for a substantial period of time, the PBS is normally supplemented with 10 to 20% serum.
Eyestone, et al., "Culture of One- and Two-Cell Bovine Embryos to the Blastocyst Stage in the Ovine Oviduct", Therioqenoloqv, Vol. 28, pp. 1-7 (1987), reported that ligated ovine oviducts would support development of bovine embryos from the l-cell to blastocyst stage. Pregnancies and live calves were produced after transfer of cultured embryos to recipient heifers. Cultures of 1- and 2-cell embryos in the oviducts of intact cycling, ovariectomized or anestrous ewes produced morphologically normal morulae and blastocysts followed by pregnancies in recipient heifers, suggesting that ovarian activity was not required for normal embryo development in the oviduct.
Another embryo culture and maintenance medium is described in parent patent application serial number 07/558,969 to Rosenkrans, Jr. et al., entitled "Bovine Embryo Medium," which is incorporated herein by reference. This embryo medium, named CR1, comprises a culture solution containing the nutritional substances necessary to support an embryo and is the preferred maintenance medium for use with this invention. The - l o - ~ 8 medium contains hemicalcium L-~actate in amounts ranging from 1.0 m~, to 10 mM, preferably 1.0 mM to 5.0 mM.
~emicalcium L-lactate is L-lactate with a hemicalcium salt incorporated thereon. Hemicalcium L-lactate is significant in that a single component satisfies two major requirements in the culture medium: 1) the calcium requirement necessary for compaction and cytoskeleton arrangement; and 2) the lactate requirement necessary for metabolism and electron transport. Hemicalcium L-lactate also serves as valuable mineral and energy source for the medium necessary for viability of the embryos.
Advantayeously, CRl medium does not contain serum, such as fetal calf serum, and does not require the use of a co-culture of animal cells or other biological media, i.e, media comprising animal cells, e.g., oviductal cells. Biological media can sometimes be disadvantageous in that they may contain trace factors which may be harmful to the embryos and which are difficult to detect, characterize and eliminate.
Examples of the main components in CR1 medium include hemicalcium L-lactate, sodium chloride, potassium chloride, sodium bicarbonate and a minor amount of fatty-acid free bovine serum albumin. Additionally, a defined quantity of essential and non-essential amino acids may be added to the medium.
Salts are added to the medium to maintain a proper osmotic pressure or osmolarity of the medium. The preferred osmotic pressure is 265 milli-osmoles (mOSM).
The concentration of salt generally ranges from 0 Mm to 155 Mm, preferably 110 mM to 115 mM. Examples of salts include sodium chloride and potassium chloride, preferably sodium chloride.
The fatty-acid free BSA is added as a surfactant, i.e., to prevent the embryos from adhering 'o each other. Unlike culture media known to the art, the CRl medium requires only a minimal amount of the fatty-acid free BSA. The fatty-acid free BSA is added in ( S
amounts ranging from 1 mg/ml to 6 mg/ml, preferably 1 mg/ml to 3 mg/ml, and most preferably 3.0 mg/ml.
Antibiotically effective amounts of an agent, such as gentamicin sulfate, penicillin, streptomycin, fungizone or other antibiotics known to the art. Additionally, a cryopreservation agent, known to the art, may be added to protect the cellular integrity of the bovine embryo during freezing operations. Further, chemical buffers, such as HEPES, may by added to maintain the proper pH in 10 the absence of CO2.
CRl medium preferably contains the following components in the following quantities:
sodium chloride - 114.7 mM
potassium chloride - 3.1 mM
sodium bicarbonate - 26.2 mM
hemicalcium L-lactate - 5 m~
fatty-acid free BSA - 3 mg/ml Oocyte The "oocyte," as used here for the recipient oocyte, means an oocyte which develops from an oogonium and, following meiosis, becomes a mature ovum. It has been found that not all oocytes are equally optimal cells for efficient nuclear transplantation in mammals. For 25 purposes of the present invention, metaphase II stage oocytes, matured either in vivo or in vitro, have been found to be optimal. Mature metaphase II oocytes may be collected surgically from either nonsuperovulated or superovulated cows or heifers 35 to 48 hours past the 30 onset of estrus or past an injection of human Chorionic Gonadotrophin (hCG) or similar hormone. Alternaiively, immature oocytes may be recovered by aspiration from ovarian follicles obtained from slaughtered cows or heifers and then may be matured in vitro in a maturation 35 medium by appropriate hormonal treatment and culturing.
As stated above, the oocyte is allowed to mature in a known maturation medium until the oocyte enters the -12~ u i~
metaphase II stage, generally 18-24 hours post aspiration. For purposes o~ the present invention, this period Or time is known as the "maturation period." As used herein for calc~1lation of time periods, "aspiration"
refers to aspiration of the immature oocytes from ovarian follicles.
Mature oocytes can be first treated with cytochalasin B at about 7.5 micrograms per milliliter, or an effectively similar microtubal inhibitor at a concentration sufficient to allow the enucleation and transfer pipette to be inserted through the zona pellucida to allow for removal of a portion of the cytoplasm without, at any point, actually rupturing the plasma membrane. The mature oocyte is first held in place by mild suction by the cell holding pipette. The enucleation and transfer pipette is then inserted through the zona pellucida of the oocyte at the point of either the metaphase II bulge or adjacent to the first polar body, i.e., in a location intended to be adjacent to the metaphase chromosomes. The pipette does not penetrate the plasma membrane. Aspiration applied through the pipette draws a portion of the cytoplasm into the pipette which includes, in the case of the metaphase II bulge, the entire bulge surrounding cytoplasm, or, in the case of the firs1- polar body, the cytoplasm adjacent to the polar body. This process is intended to draw all the metaphase chromosomes into the pipette. As the pipette is withdrawn, with suction maintained, the plasma membrane is stretched and then seals itself leaving a competent plasma membrane on the enucleated oocyte.
Maintenance Period Prior to fusing the membranes of the donor membrane-bounded nucleus and the enucleated ~ecipient oocyte together, it has been found that maintaining the nucleus and the oocyte together in the embryo maintenance medium significantly improves the development of the embryo post fusion. The nucleus and the oocyte are allowed to remain in the maintenance medium for a period of about 6-2~ hours, preferably about 10-18 hours, after the oocyte maturation period to align the oocyte adjacent the membrane of the nucleus. Calculated from oocyte aspiration, the maintenance period will be about 24-52 hours, preferably 78-42 hours, post aspiration.
Without wishing to be held to one particular explanation for the advantages of maintaining the donor embryo nucleus and the recipient oocyte in a maturation medium for an extended time prior to fusion, it is believed that the maintenance period increases the intercellular surface area contact by the creation of tiny microvilli on the surface of the donor membrane-bounded nucleus and the enucleated recipient oocyte.
With the increased amounts of microvilli, there are increased intercellular connections, i.e., projections which will attract and adhere the donor embryo nucleus to the recipient oocyte.
The transfer pipette, carr~ing the aspirated membrane-bounded nucleus, is then inserted through ~he zona pellucida of the recipient enucleated oocyte; and the membrane-bounded nucleus is deposited under the zona pellucida with lts membrane abutting the plasma membrane of the recipient oocyte.
Fusion of the Nucleus and the Oocvte At approximately 24-52 hours, preferably 28-42 hours post aspiration or, stated differently, 6-28 hours, preferably 10-18 hours, after the nucleus is positioned such that its membrane is adjacent the enucleated oocyte, the cell surface contact appears to be at its peak. It is on this basis that membrane fusion may be enhanced with the use of the maintenance period of this invention.
The onset of electricity, via the electrofusion technique, serves to induce the fusion process. Although electrofusion is preferred, it is within the scope of the ~ 3 ~ ~3 i3 ~ 8 present invention to utilize other fusion techniques.
For example, fusion can be accomplished using Sendai virus as a fusigenic agent.
In the preferred embodiment, fusion of the membrane-bounded nucleus with the enucleated recipient oocyte and simultaneous activation of the recipient oocyte are carried out by a single dielectrophoresis step using commercially available electrofusion equipment which is described below. Prior to electrofusing the donor embryo nucleus and enucleated recipient oocyte together, it is necessary to orient the cell membranes in the electric field. The term "orientation" as used herein is defined as the placement of the two cells such that the plane of contact of the two membranes, i.e., the plasma membrane of the body carrying the donor nucleus and the plasma membrane of the recipient oocyte, which will become fused together, is perpendicular to the electrical field. It has been found that random orientation results in a marked reduction in the s~ccessful fusion rate. If cells are oriented such that the fusion membranes are parallel, or at approximately a 45~ angle, to the electrical field, the rate of successful fusion will decrease. The alignment may be done electrically or mechanically. If the size of the two cells is not greatly disproportionate, a small alignment alternating-current voltage (-5 volts per millimeter at 1000 KHz) for a short time (10 seconds) will cause the cells to reorient with their membranes apposed. Repeated pulses may be needed. If the cells vary greatly in size, mechanical manipulation ~ay be required to properly orient the membranes.
The actual incorporation of a donor nucleus into an enucleated oocyte is conducted by a dielectrophoretic method of cell fusion, using a DC
current and using a non-conductive, i.e., non-ionic, media such as a mannitol solution, sorbitol or sucrose (Zimmerman) based cell fusion media. The fusion ~30~
phenomenon is the result of cell membrane breakdown and pore formation between properly oriented opposing cells.
The pores, or small channels, created between the two cells are thermodynamically unstable because of the high surface curvature of the channels and the associated high tension in the membrane. This instability causes the channels to merge and enlarge until the membranes form a single cell which contains the nucleus from the donor embryo cell.
Post-Fusion Culture ~he embryonic single-cell clones produced as described herein preferably are cultured, either in vitro or in vivo, to the morula or blastula stage. For example, the clones may be cultured in the oviduct of sheep, or other suitable animal, or in a suitable culture medium. The embryos then may be transplanted into the uteri of cattle at a suitable stage of the estrous cycle.
The procedures for transplantation are commonly known and practiced in the embryo transfer field. A percentage of these transplants will initiate pregnancies in the maternal surrogates. Animals born of these pregnancies will be genetically identical where the donor cells were from a single embryo or a clone thereof.
The following example is offered by way of illustration and not by way of limitation~
EXPERIMENTAL PROCEDURES
Source of Recipient Oocvtes and Donor Em~rvos. The oocyte-cumulus complexes (OCC) were aspirated from bovine ovaries recovered from a slaughterhouse in Milwaukee, WI.
The ovaries were transported from the slaughterhouse to the laboratory in insulated containers with saline (.9%;
30 + 2C). After arrival, the ovaries were washed with 30C water and placed into a flask containing fresh saline (.9%) in a water bath maintained at 30C.
Follicular contents were harvested by aspiration using an 18-gauge needle and accumulated in a 50 ml sterile conical tube (Falcon #2070). Following aspiration, OCC
were located using 100 mm plates in a warm room ~30 2C) using a stereomicroscope. The OCC were washed 4 times through low bicarbonate-TALP (Parrish, J. J. et al., (1988, "Capacitation of Bovine Sperm by Heparin,"
Biol. Re~rod. 38, 1171-1180, incorporated herein by reference~ and placed into maturation plates (10 OCC per 50 ul drop). Maturation plates consist of ten 50 ul drops of maturation medium with estradiol-17~ (1 ug/ml), FSH (.5 ug/ml~ and LH (.5 ug/ml) (Sirard et al., Biol.
Reprod., 39, pgs. 546-552, 1988) in a 60 mm petri dish with 10 ml of paraffin oil.
Those oocytes not used as recipient oocytes were fertilized to provide donor embryos in subsequent experiments. Fertilization of oocytes was performed according to the procedure described in Sirard et al.
(su~ra., 1988). Briefly, OCC were in vitro matured 22 +
2 hours, then washed 2 times through Sp-TALP (Parrish, J.
J. et al, supra. 1988) and moved into fertilization plates. Fertilization was performed in 60 mm plates with 10 drops (40 ~l each) of fertilization medium (5 ml TL
Stock-no glucose, 30 mg fatty-free BSA-6 mglml final, 50 ~1 pyruvate stock-0.2 mM final, 2.5 ~l gentamicin-25 ~g/ml final-optional) covered with oil and 10 OCC for each drop. The OCC were added, followed by 5 X 104 motile sperm, .2 ug of heparin, and 2 ul of PHE stock (20 ~m penicillamine, 10 ~m hypotaurine, 1 ~m epinephrine, 21 ~m sodium metabisulfate, and 118 ~m DL-lactate syrup in .9% sodium chloride according to Leibfried, M. L. and B.
D. Bavister, 1982, "Effect of Epinephrine and Hypotaurine on in vitro Fertilization in the Golden Hamster," J.
Reprod. Fertil., 66, 87-93).
Motile sperm cells were prepared by the Percoll separation of frozen sperm procedure. A 45~ percoll solution (3.090 ml/100 ml KCl, 2.920 ml/100 ml NaH2PO4, ` -17- 2~3~8 4.675 g/100 ml NaCl, 2.380 g/100 ml HEPES, adjust the pH
to 7.3) was prepared by a 1:1 dilution with 90% percoll using Sperm TL Stock Solution (SPTL) (2.10 mM CaCl22H2O, 3.1 mM KCl, 0.4 mM MgC126H20, 100 mM NaCl, 0.29 mM
NaH2P04H20, 21.6 mM Lactic Acid, 10 mM Hepes, 25 mM
NaHCO3, adjust pH to 7.4 before bringing to final volume;
check osmolarity: 290-300 mOSM) according to Parrish, J.J. et al., supra. 1988. The SPTL did not contain BSA.
Two - three ml of 90% percoll was placed on the bottom of a conical tube (Falcon 2095). Two ml of 45% percoll was layered carefully on the top of the 90% percoll. The procedure was performed at room temperature. One unit of semen was thawed (35OC, l min.) and layered on top of the percoll gradients. The tube was centrifuged at 700 x g for 30 min. The top layers were removed, and the concentrated motile sperm was available for use.
Following 44 + 2 hours after insemination, the oCc were stripped of cumulus cells, and the eggs were categorized as cleaved (> 2 cells) or uncleaved. The cleaved eggs were cultured in CRl-L-Glutamine medium for 3 to 5 days until they reach the morula or blastocyst stage.
', ~ Embryo ~a~d nipulation.
Recipient oocytes were enucleated by aspirating approximately one-eighth to one-fourth the cytoplasm juxtaposed to the polar body or the metaphase bulge using a 10-45 micron transfer pipette, leaving an enucleated membrane-bounded oocyte. Embryos were manipulated in calcium and magnesium-free TL Hepes buffered modified Tyrodes medium prepared according to Bavister et 21., "Development of Preimplantation Embryos of the Golden Hamster in a Defined Culture Medium," Biol. Reprod., 28:
235, 1983). Nuclei from later stage donor embryos were removed by aspirating the nucleus and some surrounding membrane-bounded cytoplasm from a blastomere or by aspirating an entire blastomere. Micromanipulation was ~ ~r conducted using a holding pipette having an outer diameter of approximately 120-180 microns anà an inner diameter of approximately 30 microns and a beveled, sharpened enucleation and transfer pipette having an outer diameter of approximately 10 to 45 microns. Whole blastomeres, containing nuclei, were removed from donor embryos and positioned in the perivitelline space of the recipient oocytes by the method of McGrath and Solter (supra.).
Maintenance Procedures Embryos were maintained in vitro in CR1-L-Glutamine medium for 6-18 hours prior to fusion.
Zimmerman Cell Fusion Medium (GCA Corporation, Chicago, IL), was used for fusing donor and recipient cells.
Cells from donor embryos were washed in the medium then placed in the fusion chamber with the Zimmerman medium.
Following the fusion treatment, oocytes were placed in CR1-L-Glutamine medium, in 50 microliter drops, under paraffin oil in a humidified 5% C02 in air incubator and monitored for fusion and allowed to develop for five days.
Activation and fusion of the intact, membrane-bounded nuclei to the enucleated oocytes were carried out in Zimmerman Cell Fusion Medium by dielectrophoresis using a Zimmerman ~lectrofusion Instrument, GCA
Corporation, Chicago, IL. The fusion chamber consisted of two parallel electrodes 1 mm apart on a glass slide.
The instrument was adjusted in the following manner:
Fusion voltage: 80-120 volts (DC) Electrode distance: 1 mm Alignment voltage: 1-5 volts (AC) Alignment frequency: 1000 KHz Pulse duration: 10-~0 microseconds Postfusion alignment time: 5 seconds Number of Pulses: 1-6 Experiment ~ ~' $
The experiment was designed to determine whether the development of nuclear transfer embryos (NTs) could be improved by maintaining the donor embryo cells and recipients in maintenance medium for an extended period o~ time. NTs were produced according to Prather et al., 1987, Biol. Reprod., 37,859-866, which is incorporated herein by reference. Specifically, in vitro matured oocytes were used as recipients, in vitro developed embryos were used as donors, and the subsequently formed NTs were developed in vitro in CR1 with 1 mM L-glutamine medium (CR1-L-GLN).
The treatment structure was a blocked one-way design with 3 treatments. Each donor embryo served as the block, i.e., every treatment was imposed on donor embryo cells from each donor embryo. Enucleation and transfer of donor blastomeres was performed at 24 hours post-oocyte aspiration. The three treatments were as follows: 1) fusio~ at 30 hours; Z) those that did not fuse at 30 hours and were then refused at 42 hours; and 3) fusion at 42 hours. During the manipulation process, the donor and recipient embryo cells were handled in calcium and magnesium free TALP-hepes. The cells were maintained in CR1-L-GLN during the waiting period before fusion as well as is th~ post-fusion development period.
Embryos were developed in 50 microliter drops of this maintenance medium under paraffin oil in a humidified incubator with an atmosphere of 5% C02 in air. This experiment was replicated on three different days using three morula stage donor embryos (30-4~ cells each) on each day of nuclear transfer. The results are illustrated in the following table:
-20- ~ t ~
Nuclear Transfer - Fusion at 30 Hours Versus 42 hours -~ 1 IFUS~IOIY ACTIV~.TION ¦CLEAVAGE DEVELOPMENT
MORULA +
30 hr _ BLASTOCYST
% 56.9 71 32.0 4 7+3.7b N 31/42 l9J31 7J31 ~ 80.1 6309 22.2+6.7C
% 80.4 81 71.0 32.6+5.3C
a cultured 5 days in CR1 + L-Glutamine (1 mM) b,c uncommon superscripts differ (P<0.05) The results indicate that when the fusion regime is changed to a later time period, i.e., following the maintenance period of this invention, development of NTs is simi]ar to that of normal in vitro matured, fertilized and developed oocytes. Thus, the nuclear transfer embryo appears to have increased fusion and developmental rates when fusion is delayed by approximately 4-18 hours after the time fusion would normally take place, i.e., 34-48 hours after aspiration of the recipient oocytes.
It is understood that the invention is not confined to the pzrticular construction and arrangement herein described, but embraces such modlfied forms thereof as come within the scope of the following claims.
Claims (25)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method o transferring a nucleus from a donor embryo to a recipient oocyte and culturing the nuclear transferred embryo in vitro comprising:
a. isolating a donor membrane-bounded nucleus from a cell of a donor embryo;
b. removing the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte;
c. maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte of step b. in a maintenance medium for a period of time sufficient to increase intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte; and d. fusing the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte together to form an embryonic single cell with a nucleus from the donor embryo.
a. isolating a donor membrane-bounded nucleus from a cell of a donor embryo;
b. removing the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte;
c. maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte of step b. in a maintenance medium for a period of time sufficient to increase intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte; and d. fusing the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte together to form an embryonic single cell with a nucleus from the donor embryo.
2. The method of claim 1 further comprising allowing the enucleated recipient oocyte to mature to the metaphase II stage prior to step c.
3. The method of claim 1 wherein the donor cell embryo is a bovine embryo.
4. The method of claim 1 wherein the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte are fused between approximately 6 and 28 hours after the nucleus and oocyte are maintained in the maintenance medium of step c.
5. The method of claim 1 wherein the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte are fused between approximately 10 and 18 hours after the nucleus and oocyte are maintained in the maintenance medium of step c.
6. The method of claim 1 wherein the donor membrane-bounded nucleus is a whole blastomere.
7. The method of claim 1 further comprising electrically fusing the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte.
8. The method of claim 7 further comprising, before step d., orienting the donor membrane-bounded nucleus and the enucleated recipient oocyte so that the plane of contact of their membranes is perpendicular to the direction of electric current flow.
9. The method of claim 1 further comprising maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte in a maintenance medium in step c., wherein the maintenance medium consists of co-culture with oviductal cells.
10. The method of claim 1 further comprising maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte in a maintenance medium in step c., wherein the maintenance medium consists of CR1 medium.
11. The method of claim 10 wherein the CR1 medium comprises 5 mM hemicalcium L-lactate and 0.4 mM
pyruvate.
pyruvate.
12. The method of claim 11 wherein the CR1 medium further comprises 1 mM L-glutamine.
13. A method for producing cloned mammalian embryos comprising:
a. isolating a donor membrane-bounded nucleus from a cell of a donor embryo;
b. removing the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte;
c. maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte of step b. in a maintenance medium for a period of time sufficient to increase intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte; and d. electrically inducing cell fusion between the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte to form an embryonic single cell with a nucleus from the donor.
a. isolating a donor membrane-bounded nucleus from a cell of a donor embryo;
b. removing the nuclear chromosomal material from an oocyte to create an enucleated recipient oocyte;
c. maintaining the donor membrane-bounded nucleus and the enucleated recipient oocyte of step b. in a maintenance medium for a period of time sufficient to increase intercellular surface area contact between the donor membrane-bounded nucleus and the enucleated recipient oocyte; and d. electrically inducing cell fusion between the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte to form an embryonic single cell with a nucleus from the donor.
14. The method of claim 13 wherein the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte are fused between approximately 6 and 28 hours after the nucleus and oocyte are maintained in the maintenance medium of step c.
15. The method of claim 13 wherein the membranes of the donor membrane-bounded nucleus and the enucleated recipient oocyte are fused between approximately 10 and 18 hours after the nucleus and oocyte are maintained in the maintenance medium of step c.
16. The method of claim 14 wherein the donor embryo is a bovine embryo.
17. The method of claim 16 further comprising placing the donor membrane-bounded nucleus and the enucleated recipient oocyte in a maintenance medium in step c., wherein the maintenance medium consists of co-culture with oviductal cells.
18. The method of claim 16 further comprising placing the donor membrane-bounded nucleus and the enucleated recipient oocyte in a maintenance medium in step c., wherein the maintenance medium consists of CR1 medium.
19. The method of claim 18 wherein the CR1 medium comprises 5 mM hemicalcium L-lactate and 0.4 mM
pyruvate.
pyruvate.
20. The method of claim 18 wherein the CR1 medium further comprises 1 mM L-glutamine.
21. An improved method for producing cloned mammalian embryos by transferring a nucleus from a donor mammalian embryo to an enucleated recipient oocyte and culturing the nuclear transfer embryo in vitro, the improvement comprising maintaining the donor nucleus adjacent to the enucleated recipient oocyte in a maintenance medium for a period of time sufficient to increase intercellular surface area contact between the donor nucleus and the enucleated recipient oocyte.
22. The method of claim 21 in which such position is maintained until microvilli form on the surface of said oocyte.
23. The method of claim 22 in which such position is maintained until said microvilli attract and adhere the donor embryo nucleus to the recipient oocyte.
24. The method of claim 21 in which such position is maintained for between about 6 to about 28 hours in the maintenance medium.
25. The method of claim 21 in which such position is maintained for between about 10 to about 18 hours in the maintenance medium.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58896990A | 1990-07-26 | 1990-07-26 | |
US07/588,969 | 1990-07-26 | ||
US60641890A | 1990-10-31 | 1990-10-31 | |
US07/606,418 | 1990-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2043088A1 true CA2043088A1 (en) | 1992-01-27 |
Family
ID=27080414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2043088 Abandoned CA2043088A1 (en) | 1990-07-26 | 1991-05-23 | Method of cloning mammalian embryos |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2043088A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
-
1991
- 1991-05-23 CA CA 2043088 patent/CA2043088A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5453366A (en) | Method of cloning bovine embryos | |
CA1338931C (en) | Multiplying bovine embryos | |
US5096822A (en) | Bovine embryo medium | |
EP0739412B1 (en) | ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS | |
US6215041B1 (en) | Cloning using donor nuclei from a non-quiesecent somatic cells | |
Robl et al. | Prospects for the commercial cloning of animals by nuclear transplantation | |
WO1999005266A2 (en) | Trans-species nuclear transfer | |
US20050273870A1 (en) | Preparation and selection of donor cells for nuclear transplantation | |
Keskintepe et al. | Caprine blastocyst formation following intracytoplasmic sperm injection and defined culture | |
CA2403344C (en) | Effective nuclear reprogramming in mammals | |
Manik et al. | Micromanipulation and cloning studies on buffalo oocytes and embryos using nucleus transfer | |
Eyestone et al. | Nuclear transfer from somatic cells: applications in farm animal species | |
Van Stekelenburg‐Hamers et al. | Nuclear transfer and electrofusion in bovine in vitro‐matured/in vitro‐fertilized embryos: Effect of media and electrical fusion parameters | |
CA2043088A1 (en) | Method of cloning mammalian embryos | |
EP0559307A1 (en) | Maturation procedure of the recipient ocytes for multiplying bovine embryos | |
Hyttel et al. | RNA synthesis in porcine blastomere nuclei introduced into in vitro matured ooplasm | |
US20040077077A1 (en) | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same | |
WO2001030970A2 (en) | Improved protocol for activation of oocytes | |
Reggio et al. | Nuclear transfer embryos in the horse | |
RU2205537C2 (en) | Method for obtaining cloned tiger due to applying method of interspecific nuclear transplantation | |
AU2002248983B2 (en) | A method of nuclear transfer | |
WO2024086514A1 (en) | Production of livestock animals from embryonic stem cells | |
US20040064845A1 (en) | Method of cloning animals | |
Dai et al. | Clone of Chinese Jinan redcross yellow cattle and evaluation of reproductive characteristics of cloned calf | |
Ogura et al. | Microinsemination using spermatogenic cells in mammals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |